VERNON HILLS, IL--(Marketwire - January 05, 2010) - Applied NeuroSolutions, Inc. (OTCBB: APSN)
(www.AppliedNeuroSolutions.com), a biotechnology company focused on the
development of products for the early diagnosis and treatment of
Alzheimer's disease ("AD"), today announced that Craig S. Taylor, Ph.D.,
its President and Chief Executive Officer, will present an overview of the
Company at the OneMedPlace Finance Forum. Dr. Taylor's presentation will
be on Tuesday, January 12, 2010 at 1:45 p.m. Pacific Time at the Sir
Francis Drake Hotel in San Francisco.
Dr. Taylor will provide an overview of Applied NeuroSolutions, Inc.,
including its Alzheimer's disease drug development collaboration with Eli
Lilly and Company, and its AD diagnostic programs.
About Applied NeuroSolutions:
Applied NeuroSolutions, Inc. (OTCBB: APSN) is developing diagnostics and
therapeutics to detect and treat Alzheimer's disease (AD) building on
discoveries originating from the Albert Einstein College of Medicine.
Applied NeuroSolutions is in a collaboration with Eli Lilly and Company to
develop novel therapeutic compounds to treat the progression of AD. For
its diagnostic pipeline, Applied NeuroSolutions is focused on both serum
and cerebrospinal fluid (CSF) tests to detect AD at a very early stage.
The CSF based P-Tau 231 test now being offered for use in clinical trials
can effectively differentiate AD patients from those with other
neurological diseases that have similar symptoms. There is currently no FDA
approved diagnostic test to detect AD. Alzheimer's disease currently
afflicts over five million Americans, and the world market for AD therapy
is currently estimated to be nearly 35 million patients. For more
information, visit www.AppliedNeuroSolutions.com
This press release contains forward-looking statements about Applied
NeuroSolutions. The company wishes to caution the readers of this press
release that actual results may differ from those discussed in the
forward-looking statements and may be adversely affected by, among other
things, the risks associated with new product development and
commercialization, clinical trials, intellectual property, regulatory
approvals, potential competitive offerings, and access to capital. For
further information, please visit the company's website at
www.AppliedNeuroSolutions.com, and review the company's filings with the
Securities and Exchange Commission.
